Every 8-K that GENVOR INC (GNVR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GNVR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNVR filings page.
Genvor Incorporated updated its financing arrangement with Evergreen Capital Management through a side letter tied to an existing securities purchase agreement. The original deal allowed up to $800,000 of convertible promissory notes and warrants with an aggregate purchase price of up to $666,668, funded in four tranches.
Under the new letter, Evergreen’s registration and piggyback registration rights were removed, and the total warrants that may be issued rose from 600,000 to up to 1,200,000. Evergreen accelerated funding of the second and third tranches, giving Genvor gross proceeds of $333,334 on June 17, 2026, while the fourth tranche of $166,667 is now exercisable at Evergreen’s option until the note’s maturity.
In connection with this funding, Genvor issued a five-year warrant to Evergreen to purchase up to 300,000 common shares at $1.00 per share, with cashless exercise permitted after six months if the market price exceeds the exercise price and the warrant shares remain unregistered. The warrant and its underlying shares were issued as unregistered securities under Section 4(a)(2) of the Securities Act.
Genvor Incorporated appointed Donald Kalkofen as Chief Financial Officer effective May 18, 2026, initially via a services agreement with Wave Financial Consulting LLC that was amended and restated on May 21, 2026.
Mr. Kalkofen is an experienced biotech CFO with more than 20 years of finance leadership and public company and IPO experience. His amended agreement provides $6,250 in monthly cash compensation and $7,750 in deferred monthly cash compensation through 2026, with cash compensation increasing to $14,000 per month starting January 1, 2027. He is eligible for ten-year options to purchase up to 575,000 shares of common stock, subject to Board approval of an equity plan, shareholder approval, and the effectiveness of a Form S-8 registration statement before the options become exercisable.
Genvor Incorporated created a new Series C Preferred Stock class and issued one share under an existing advisory agreement. On May 5, 2026, the company filed a certificate of designation in Nevada setting aside four shares as Series C Preferred Stock with a par value of $0.001 per share.
These shares carry standard voting and dividend rights but preferential conversion rights into common stock. Each Series C share may convert, at the holder’s option, into common stock based on a $300,000 value divided by a specified market price formula that depends on whether Genvor is listed on a national exchange by April 14, 2027. On May 8, 2026, one Series C share was issued to Brio Advisory Group LLC as consideration under an advisory agreement, relying on a private offering exemption from registration.
Genvor Incorporated entered a securities purchase agreement with Evergreen Capital Management LLC, issuing a convertible promissory note of up to $800,000 and warrants to buy up to 600,000 common shares for a purchase price of up to $666,668, paid in four tranches.
The note carries 10% annual interest, matures the earlier of nine months from the April 15, 2026 issue date or an Exchange Listing, and is generally convertible at $1.00 per share, with a lower default conversion formula and a 4.99% beneficial ownership cap. The five-year cashless warrants have a $1.00 initial exercise price, adjustable to the note’s conversion price.
Genvor also signed an Advisory Agreement with Brio Advisory Group, under which Brio provides strategic and financing advice in exchange for preferred stock valued at $300,000 per funding tranche, or equivalent common stock if no Exchange Listing occurs within one year, subject to a minimum $1.00 per-share valuation.